IGDRASOL had earlier acquired exclusive US distribution rights to Cynviloq, which is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries, including South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and ovarian cancer.
IGDRASOL chief executive officer Vuong Trieu said, "We look forward to potentially making this important drug, Cynviloq, available to cancer patients who would greatly benefit from it – initially as an alternative to Abraxane and potentially in the future as a treatment option for indications such as bladder and ovarian cancers."
According to an option agreement, entered into in March 2013, STI has the right to acquire IGDRASOL.